Israeli Study: Pfizer Coronavirus Vaccine Is 91 Percent Effective At Preventing Infection
A joint study with Israeli HMO Maccabi and the Technion, which included data from 1.7 million Israelis, shows protection against coronavirus peaks 35 days after first jab, at 99.3 percent
Two weeks after the second dose of the Pfizer-BioNTech coronavirus vaccine is given, it is 99% effective in preventing symptomatic COVID-19 and 91.2% in preventing infection.
The data is among the findings of an analysis of the electronic health records of 1.7 million Israelis. Conducted by Maccabi Health Services and the Technion Israel Institute of Technology, the study shows the effectiveness of the Pfizer vaccine gradually increasing starting at 12 days after the first dose and reaching maximum effectiveness at around 35 days .
Latest Study Shows Two Shots Of Pfizer Vaccine Effective Vs Delta
- Two doses of Pfizer’s Covid vaccine are nearly as effective at preventing infection with the Delta variant as they are against the Alpha variant.
- The findings are based on vaccinations in England and were published in a reputable journal this week.
- The authors said this underscores the importance of people receiving both doses.
With the highly infectious Delta coronavirus variant having only recently begun to dominate Covid-19 infections in some countries, the effectiveness of vaccines against this variant has been unclear.
The latest, real-world data from England, however, show that people fully vaccinated with the Pfizer-BioNTech vaccine were 88% protected against symptomatic infection with the Delta variant. In people who had received only the first dose, the effectiveness was just 30.7%, underscoring the importance of getting the second shot.
The study was published this week in the New England Journal of Medicine and was led by Dr Jamie Lopez Bernal from Public Health England .
The researchers compared the effectiveness of the vaccine against the Delta variant with its effectiveness against the Alpha variant , which was the predominant virus variant between January and May 2021 in the UK before the Delta variant took over, causing a surge in cases. The vaccine was found to be 48.7% effective after the first shot and 93.7% after the second shot.
Limitations of study
AstraZeneca vaccine also tested
Pfizer booster shot
Deal with SA facility
Catching And Passing On Covid
The Pfizer vaccine is effective at reducing the number of people who get COVID-19.
Its harder to find out how well the vaccine stops people passing on the COVID-19 virus. Recent studies show that the Pfizer vaccine can reduce transmission of the virus. These studies looked at the number of people infected with COVID-19 after theyd been vaccinated and their close contacts.
You May Like: How Long To Get Covid Results From Cvs
Which Vaccine Is Best
All COVID-19 vaccines give you good protection from severe illness from COVID-19 when you are fully vaccinated. The HSE only uses a vaccine if it meets the required standards of safety and effectiveness.
Pfizer/BioNTech or Moderna are the recommended vaccines for people under the age of 50. This is because of the very rare risk of unusual blood clots with low platelets in people under 50 who get the AstraZeneca or Janssen vaccines.
Extending The Gap Between Doses
Early findings from a small number of well-designed studies show that an extended gap between doses of the Pfizer vaccine gives at least an equally robust immune response.
There will be some exceptions. For example, if you are on a specific clinical treatment plan or are at higher risk of contracting COVID-19, you may be advised to have a shorter gap between doses.
The minimum gap between doses will continue to be 21 days.
Recommended Reading: How Long Cvs Covid Test Results
Pfizer Vaccine Works Against Coronavirus Mutation In Uk And S Africa Variants
Vaccines will likely continue to work against these new strains.
Pfizer’s coronavirus vaccine is effective against a key mutation found in variants of the virus that are spreading faster than the original strain, according to an early study.
While viruses mutate all the time, scientists worry that some of the new mutations in the novel coronavirus, specifically those in a new variant discovered in South Africa, may make vaccines less effective, Live Science previously reported. The South Africa variant, known as 501.V2, as well as another variant discovered in the U.K. known as B.1.1.7, both seem to spread more easily than the original virus, likely because they both have some of the same mutations in the SARS-CoV-2 spike protein, the weapon the virus uses to invade human cells.
Scientists are now working to understand how these mutations might impact the effectiveness of COVID-19 vaccines. A group of researchers from Pfizer and the University of Texas Medical Branch in Galveston generated a version of the coronavirus that included a mutation called N501Y, which is present on the spike protein of both the variants found in the U.K. and South Africa.
“Such a vaccine update would be facilitated by the flexibility of mRNA-based vaccine technology,” they added.
Originally published on Live Science.
Efficacy Across Different Groups
A consistently high efficacy was observed in the clinical trials across age groups, sex, race, ethnicity and people with underlying medical conditions.
This means after getting two doses of the Pfizer vaccine, more than 9 out of 10 people are protected against COVID-19 regardless of their age, health status or ethnic group.
Don’t Miss: Cvs Covid Testing How Long For Results
If The Gap Between Your Appointments Is Less Than 6 Weeks
If you have already booked and the gap between your appointments is less than 6 weeks, you can keep the second appointment or choose to change it.
The important thing is to get 2 doses of the vaccine to be fully vaccinated.
To cancel or modify your booking you can:
- call the COVID Vaccination Healthline on .
Study Shows Pfizer Covid
A study published on Monday in The Lancet medical journal found that the efficacy of the Pfizer-BioNTech COVID-19 vaccine fell below 50 percent after about six months after the second dose.
The Pfizer-funded study found that Pfizer’s vaccine was 88 percent effective in the first month after full vaccination but dropped to 47 percent effectiveness at about six months. The vaccine was also found to be highly effective against the delta variant, which was found to be over 90 percent effective in the first months before dropping to 53 percent effectiveness after four months.
Researchers determined that the waning immunity had to do with the amount of time since an individual was given the second shot rather than due to the highly infectious delta strain.
“Our results provide support for high effectiveness of against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant,” the researchers wrote. “Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection.”
Protection against hospital admission remained high throughout, being 93 percent effective up to six months after administration.
- Delivered to your inbox midday
You May Like: How Much Is Covid Test At Cvs
If You Value Our Coronavirus Coverage Please Consider Making A One
But since the J& J vaccines arrival on the scene there have been a number of challenges. A production snafu in the hands of a contract production company contaminated 15 million doses, which had to be destroyed. And in mid-April, the FDA and CDC recommended states pause use of the vaccine as they investigate whether the vaccine triggers a rare but serious side effect the development of diffuse blood clots, even though the few individuals who developed the condition had low platelet levels.
How Well The Vaccine Works
- Based on evidence from clinical trials in people 16 years and older, the Pfizer-BioNTech vaccine was 95% effective at preventing laboratory-confirmed infection with the virus that causes COVID-19 in people who received two doses and had no evidence of being previously infected.
- In clinical trials, the Pfizer-BioNTech vaccine was also highly effective at preventing laboratory-confirmed COVID-19 infection in adolescents 1215 years old, and the immune response in people 1215 years old was at least as strong as the immune response in people 1625 years old.
- The vaccine was also highly effective in clinical trials at preventing COVID-19 among people of diverse age, sex, race, and ethnicity categories and among people with underlying medical conditions.
- Evidence shows mRNA COVID-19 vaccines offer similar protection in real-world conditions as they have in clinical trial settingsreducing the risk of COVID-19, including severe illness by 90% or more, among people who are fully vaccinated.
- CDC will continue to provide updates as we learn more.
Read Also: How Fast Does Cvs Give Covid Results
Patient And Public Involvement
Members of the public were not directly involved in this study as this was an unfunded study using routine surveillance data sources. The study was, however, conducted in consultation with advice from the UK Joint Committee on Vaccination and Immunisation, which includes lay membership to represent the perspective of patients or users of NHS services.
J& j Vaccine Effectively Helps Protect Against Hospitalization And Death From Covid
So far, over 14 million people in the U.S. have received the J& J vaccine. But ever since it was authorized, the J& J vaccine has experienced some media challenges. The vaccines reported effectiveness has differed from that of the mRNA vaccines, and its use was temporarily paused earlier this year due to concerns over rare blood clots.
In initial clinical trials, the vaccine was about 66% effective at preventing COVID-19 infections. This drew some media attention at face value it seemed less effective than the other vaccines. But the vaccine was studied under different conditions.
Fast forward to today, and more data is available that speaks to its effectiveness. In early July, data from two studies showed that one dose of the vaccine provides immune protection that lasts for at least 8 months. These studies have not yet been published, but they were reported by Johnson & Johnson.
Also, in early August, a large South African study referred to as the Sisonke study showed that the vaccine was about 95% effective against death and 71% effective against hospitalization due to the Delta variant in healthcare workers.
- What this means: The J& J vaccine, like the mRNA vaccines, is considered effective against the COVID-19 Delta variant.
- What this doesnt mean: The J& J vaccine should be preferred over the other vaccines.
To read more about this data, click or tap here.
You May Like: How Long Does Cvs Take To Get Covid Results
An Unchartered Situation For All Of Us: From Shipping Containers To Security Concerns A Covid
Modernas must be shipped at -4 degrees Fahrenheit, which is within the temperature of a regular refrigerator freezer.
After thawing, a vial of the Pfizer vaccine must be used within five days Modernas is stable at fridge temperature for 30 days and at room temperature for 12 hours. J& Js vaccine can be stored at room temperature not to exceed 77 degrees Fahrenheit for 12 hours when the vial hasnt yet been punctured. After the first dose is withdrawn, the vial can be stored in a fridge for six hours or at room temperature for two hours.
No ‘black And White’ Winners Yet
While most studies to date have looked at how effective vaccines are at reducing the risks of symptomatic disease, admission to hospital and death, a massive pre-print study out of the UK looked at how vaccines reduced the risk of catching the virus at all.
The University of Oxford study looked at more than 350,000 COVID-19 test results taken as part of a survey between May and August this year, when the Delta strain was dominating outbreaks.
Samples were taken at random, regardless of symptoms, and researchers recorded information such as what vaccination people had been given and how long ago they had been vaccinated.
It found that, 14 days after a second dose of AstraZeneca or Pfizer, those vaccines were, on average, about 67 per cent and 80 per cent effective against testing positive for COVID-19.
Both vaccines’ effectiveness reduced slightly over time, but Pfizer’s effectiveness appeared to drop faster than AstraZeneca’s. After a few months, the effectiveness levels converged.
However, this a complex area of research and studies are still under way, said University of Sydney’s centre for virus research director, Tony Cunningham.
“You’ve got to be very cautious about being too black and white at this stage. We’re still learning,” he said.
Professor Cunningham also said there were many factors that played into how effective vaccines were over time, such as age and immuno-compromising conditions.
You May Like: How Long Do Cvs Covid Tests Take
Newest Data Suggests Second Shot Provides Better Protection Against Variants
Real-word data from the UK posted May 23 by Public Health England showed that Pfizer’s and AstraZeneca’s COVID-19 vaccines worked better against the variants when two doses were given rather than just one. Both vaccines were 30% effective against COVID-19 with symptoms caused by the Delta variant, first identified in India, three weeks after the first dose.
This was boosted to between 60% and 88% effectiveness two weeks after the second dose. The two vaccines were 50% effective against COVID-19 with symptoms against the variant first found in the UK, Alpha, three weeks after the first dose. This increased to between 66% and 93% two weeks after the second dose.
Dr. Anthony Fauci, President Joe Biden’s chief medical advisor, said on June 8 that getting two doses of COVID-19 vaccines would stop the Delta variant from spreading across the US. In the UK, Professor Deborah Dunn-Walters, chair of the British Society for Immunology COVID-19 Taskforce, said in a statement on June 4 that two doses of Pfizer’s vaccine were “critical for protection” against emerging strains of the virus.
Study Indicates Pfizer Covid
A study released in The Lancet medical journal found that the efficacy of the Pfizer-BioNTech COVID-19 vaccine fell below 50 percent after about six months after the second dose.
The data indicates the decline was not dependent on the strain of the coronavirus causing an infection.
The Pfizer-funded study found that Pfizers vaccine was 88 percent effective in the first month after full vaccination but dropped to 47 percent effectiveness at about six months. The vaccine was also found to be highly effective against the delta variant, which was found to be over 90 percent effective in the first months before dropping to 53 percent effectiveness after four months.
Researchers determined that the waning immunity had to do with the amount of time since an individual was given the second shot rather than due to the highly infectious delta strain,
However, company representatives assert that the data also shows that the vaccines help prevent hospitalizations and deaths, and the third booster shot will offer reliable protection against the serious Delta variant.
And while all of this data seems to be positive, the data also reveals the vaccines are not 100% effective against death. A review of the numbers in deep-blue Vermont shows that 76% of September COVID-19 deaths were vaccine breakthrough cases.
Recommended Reading: How Long Does It Take For Cvs Covid Test Results
Pfizer Vaccine Highly Effective Against Covid
According to research published in The Lancet journal on Tuesday , two doses of the Pfizer COVID-19 vaccine are 90 percent effective against hospitalization from the disease for at least six months for all variations, including Delta.
The researchers discovered that the vaccines effectiveness against allS-COV-2 infections decreased with time, falling from 88% within one month after getting two vaccine doses to 47% after six months.
They did say, however, that the overall effectiveness of the Pfizer vaccine against hospitalizations remained at 90% for all variations.
According to the researchers, the study highlights the necessity of increasing COVID-19 immunization rates worldwide and monitoring vaccine effectiveness to determine which people should be given booster shots first.
Our study confirms that vaccines are a critical tool for controlling the pandemic and that they remain highly effective in preventing severe disease and hospitalization, including from the Delta and other variants of concern, said Sara Tart of Kaiser Permanente in the United States, the studys lead author.
In the months following a second treatment, protection against infection decreases, Sara Tartof stated.
People in many nations throughout the world have not yet had a primary vaccination series, according to the researchers, therefore considerations for booster doses should take global COVID-19 vaccine availability into account.
Cdc Report Finds That Covid
A recent Centers for Disease Control and Prevention report analyzing data from December 2020 to August 2021 found that full vaccination was about 80% effective at preventing COVID-19 infection among frontline workers.
This percentage, however, takes into account both Alpha and Delta variants, rather than addressing the Delta variant specifically. Before the Delta variants predominance, this percentage was closer to 91%. After it became predominant in the summer months, the number from this study dropped to about 66%. Today, the Delta variant represents almost 99% of U.S. COVID-19 cases.
However, this study doesnt represent everyone it only comes from about 3,000 vaccinated frontline workers across eight different U.S. locations. The report also cautioned that these findings might be impacted by how long ago some completed their vaccination series, since general vaccine effectiveness may wane over time.
- What this means: Preliminary data says that COVID-19 vaccines may provide less protection against the Delta variant compared to previous strains of the virus, but theyre still considered effective.
- What this doesnt mean: COVID-19 vaccines arent effective against the Delta variant. COVID-19 vaccines, in addition to other precautions, remain the best defense against COVID-19.
To read more about this report, click or tap here.
You May Like: How Long Cvs Covid Test Results